Am Soc Clin Oncol Educ Book
-
Publication Venue For
- Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations.. 41:1-5. 2021
- Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.. 40:161-173. 2020
- What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care.. 40:55-70. 2020
- Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.. 40:1-15. 2020
- The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.. 40:1-8. 2020
- Financial Toxicity and Equitable Access to Clinical Trials.. 39:11-18. 2019
- "How Much Time Do I Have?": Communicating Prognosis in the Era of Exceptional Responders.. 38:787-794. 2018
- Complexity of Delivering Precision Medicine: Opportunities and Challenges.. 38:998-1007. 2018
- Multidisciplinary Management of Oligometastatic Soft Tissue Sarcoma.. 38:939-948. 2018
- Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies.. 38:716-725. 2018
- Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.. 38:239-247. 2018
- How Should We Intervene on the Financial Toxicity of Cancer Care? One Shot, Four Perspectives.. 37:35-39. 2017
- Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma.. 37:337-342. 2017
- Discussing the Evidence for Upstream Palliative Care in Improving Outcomes in Advanced Cancer.. 35:e534-e538. 2016
- Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.. 35:e277-e282. 2016
- Treatment of Lung Cancer in Medically Compromised Patients.. 35:e484-e491. 2016
- Tumor Heterogeneity and Therapeutic Resistance.. 35:e585-e593. 2016
- Surgery or ablative radiotherapy for breast cancer oligometastases.. e8-15. 2015
- Accelerated aging among cancer survivors: from pediatrics to geriatrics.. e423-e430. 2014
- Can we maximize both value and quality in gynecologic cancer care? A work in progress.. e268-e275. 2014
- Models of cancer survivorship health care: moving forward.. 205-213. 2014
- Biomarkers and correlative endpoints for immunotherapy trials. 2013
- Individualizing treatment decisions for older adults with hematologic malignancies.. 208-219. 2013
- Mammographic density: intersection of science, the law, and clinical practice. 2013
- The ethics of health information technology in oncology: emerging isssues from both local and global perspectives.. 136-142. 2013
- Thrombosis and cancer: emerging data for the practicing oncologist. 2013